MA26779A1 - Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central. - Google Patents

Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.

Info

Publication number
MA26779A1
MA26779A1 MA26339A MA26339A MA26779A1 MA 26779 A1 MA26779 A1 MA 26779A1 MA 26339 A MA26339 A MA 26339A MA 26339 A MA26339 A MA 26339A MA 26779 A1 MA26779 A1 MA 26779A1
Authority
MA
Morocco
Prior art keywords
arenesulfonyl
pyrrolidine
aryl
treatment
nervous system
Prior art date
Application number
MA26339A
Other languages
English (en)
Inventor
Eric Vieira
Jurgen Wichmann
Vincent Mutel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26779A1 publication Critical patent/MA26779A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
MA26339A 1999-03-25 2001-09-25 Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central. MA26779A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
MA26779A1 true MA26779A1 (fr) 2004-12-20

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26339A MA26779A1 (fr) 1999-03-25 2001-09-25 Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.

Country Status (34)

Country Link
US (1) US6284785B1 (fr)
EP (1) EP1165510B1 (fr)
JP (1) JP3590589B2 (fr)
KR (1) KR100452648B1 (fr)
CN (1) CN1150165C (fr)
AR (1) AR028817A1 (fr)
AT (1) ATE305451T1 (fr)
AU (1) AU765212B2 (fr)
BR (1) BR0009278A (fr)
CA (1) CA2368418C (fr)
CO (1) CO5050296A1 (fr)
CZ (1) CZ20013402A3 (fr)
DE (1) DE60022867T2 (fr)
DK (1) DK1165510T3 (fr)
ES (1) ES2249249T3 (fr)
HK (1) HK1044944B (fr)
HR (1) HRP20010682A2 (fr)
HU (1) HUP0200284A3 (fr)
IL (1) IL145301A0 (fr)
JO (1) JO2274B1 (fr)
MA (1) MA26779A1 (fr)
MX (1) MXPA01009623A (fr)
MY (1) MY125295A (fr)
NO (1) NO319948B1 (fr)
NZ (1) NZ514037A (fr)
PE (1) PE20001583A1 (fr)
PL (1) PL204436B1 (fr)
RU (1) RU2248350C2 (fr)
SI (1) SI1165510T1 (fr)
TR (1) TR200102789T2 (fr)
TW (1) TW575561B (fr)
WO (1) WO2000058285A1 (fr)
YU (1) YU67601A (fr)
ZA (1) ZA200107689B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
WO2005113542A2 (fr) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
CA2582777A1 (fr) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
PT1919865E (pt) 2005-08-30 2011-07-11 Takeda Pharmaceutical Derivados de 1h-pirrole substituídos com 1-heterociclilsulfonilo, 2-aminometilo, 5-(hetero)arilo como inibidores da secreção ácida
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
TWI473798B (zh) 2008-08-27 2015-02-21 Takeda Pharmaceutical 吡咯化合物
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) * 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
BR0009278A (pt) 2001-12-26
EP1165510B1 (fr) 2005-09-28
US6284785B1 (en) 2001-09-04
HK1044944B (zh) 2004-10-21
JP2002540191A (ja) 2002-11-26
CA2368418C (fr) 2009-03-10
CN1150165C (zh) 2004-05-19
IL145301A0 (en) 2002-06-30
ES2249249T3 (es) 2006-04-01
TW575561B (en) 2004-02-11
CA2368418A1 (fr) 2000-10-05
CN1345311A (zh) 2002-04-17
KR20010108403A (ko) 2001-12-07
MY125295A (en) 2006-07-31
WO2000058285A1 (fr) 2000-10-05
KR100452648B1 (ko) 2004-10-12
EP1165510A1 (fr) 2002-01-02
HUP0200284A2 (en) 2002-06-29
RU2248350C2 (ru) 2005-03-20
YU67601A (sh) 2004-09-03
AU3291500A (en) 2000-10-16
CZ20013402A3 (cs) 2002-03-13
JP3590589B2 (ja) 2004-11-17
DK1165510T3 (da) 2006-02-06
ATE305451T1 (de) 2005-10-15
NO20014617L (no) 2001-09-24
ZA200107689B (en) 2002-12-18
HK1044944A1 (en) 2002-11-08
AR028817A1 (es) 2003-05-28
HRP20010682A2 (en) 2002-10-31
JO2274B1 (en) 2005-04-07
CO5050296A1 (es) 2001-06-27
DE60022867T2 (de) 2006-06-22
AU765212B2 (en) 2003-09-11
TR200102789T2 (tr) 2002-04-22
NO20014617D0 (no) 2001-09-24
NO319948B1 (no) 2005-10-03
DE60022867D1 (de) 2006-02-09
MXPA01009623A (es) 2002-05-06
PL204436B1 (pl) 2010-01-29
PE20001583A1 (es) 2001-01-15
PL350679A1 (en) 2003-01-27
NZ514037A (en) 2004-01-30
SI1165510T1 (sl) 2005-12-31
HUP0200284A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
HUP0103856A2 (hu) Gyógyszerkészítmény akut rendellenességek kezelésére
AU7137000A (en) Electronic stimulation system for treating tinnitus disorders
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
NO991734D0 (no) Pyrazolinoner for behandling av potensforstyrrelser
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
NO974569L (no) Benzamider for behandling av neurodegenerative forstyrrelser
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
HUP9904030A3 (en) Use of tiagabine for production of pharmaceutical against psychotic disorders
MA26908A1 (fr) S-methyl-dihydro-ziprasidone pour le traitement de troubles psychiatriques et oculaires
AR026062A1 (es) Tratamiento de desordenes oculares
NO20001894D0 (no) Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer
PL347976A1 (en) Isonipecotamides for the treatment of integrin−mediated disorders
PT1305307E (pt) Derivados de indole eficazes no tratamento de doencas do sistema nervoso central
FR2774289B1 (fr) Medicament pour le traitement des dereglements de l'apoptose
NO20012538D0 (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet